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Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune
responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The
fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present
a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory
molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies,
T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical
trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being
vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This
review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based
cancer vaccination.
Copyright © 2009 Shigeo Koido et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Cancer Vaccine
Cancer vaccine is treatment that enhances the patient’s
own immune system. The antigen-presenting cells (APCs)
most suitable for cancer vaccine are dendritic cells (DCs),
which can be distinguished from B cells and macrophages by
their abundant expression of costimulatory molecules and
ability to initiate a strong primary immune response [1].
A major area of investigation in cancer vaccine involves the
design of DC-based cancer vaccines [2]. DCs are specialized
to capture and process tumor-associated antigens (TAAs),
converting the proteins to peptides that are presented on
major histocompatibility complex (MHC) class I and class
II molecules. DCs then migrate to T-cell areas of secondary
lymphoid organs and become competent to present antigens
to T cells, thus initiating antigen-specific immune responses
[1, 2]. Ex vivo generated, antigen-loaded DCs have been used
as vaccines to improve immunity. But there is considerable
controversy as to which forms of antigen loading are most
effective. Different strategies have been developed to load
DCs with TAAs, including synthetic peptides derived from
the known antigens [3], tumor lysates [4], tumor RNA [5],
and dying tumor cells [6] to induce antigen-specific immune
responses. These DCs have been concomitantly treated with
conditioning factors such as a standard mixture of cytokines
(TNF-a, IL-1β, IL-6, and PGE2) [7] or Toll-like receptors
(TLRs) [8] that induce DC maturation, thus converting them
into potent APCs. The immunogenicity of antigens delivered
by DCs has been shown in patients with cancer [4]. Although
clinical trials have demonstrated immunological responses
after vaccination with DCs loaded with tumor specific pep-
tides, the efficacy of therapeutic vaccination against cancer
has recently been questioned because of the undeniably
limited rate of objective tumor regressions that has been
observed in clinical trials [9]. However, several aspects of
DC vaccination require optimization to improve clinical
responses including the facilitation of innate and adaptive
interactions and reduction of regulatory T cell (Treg)
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Figure 1: Fusions of autologous DCs and autologous tumor cells. The DCs/tumor fusion cells express MHC class I and class II and
costimulatory molecules as well as tumor-associated antigens. The fusions are able to process tumor-derived peptides and MHC class I
peptides derived from DCs. They form MHC class I-peptide complexes, in the endoplasmic reticulum, which are transported to the surface
and presented to CD8+ T cells. Similarly, the fusion cells can also synthesize MHC class II peptides derived from DCs in the endoplasmic
reticulum, which are transported to the cytoplasm where MHC class II-peptide complexes are assembled with tumor-derived peptides. These
complexes are presented to CD4+ T cells, which are important for efficient CTL induction.
networks or suppressive tumor-microenvironments that inh-
ibit the function of antitumor immune responses [10].
2. Antitumor Immunity by DCs/Tumor
Fusions in Animal Model
Effective delivery of antigens into DCs is an important aspect
for clinical trials. Vaccination with DCs loaded with tumor
specific peptides has been used [3, 4, 11]. However, a major
drawback of this strategy comes from a limited number of
known tumor peptides available in many HLA contexts and
the potential evasion of immunological targeting through
downregulation of their antigens. To solve this problem,
an alternative approach has been developed by fusing DCs
with tumor cells [12]. In this approach, a broad spectrum
of TAAs, including those known and unidentified, can be
fully presented on MHC class I and class II molecules in the
context of costimulatory molecules (Figure 1) [13, 14].
The fusion of syngeneic DCs and tumor cells creates
a heterokaryon with both tumor-derived antigens and
DCs-derived MHC class II costimulatory molecules (B7.1
and B7.2), intracellular adhesion molecule- (ICAM-) 1,
lymphocyte function-associated antigen- (LFA-) 1 and −3,
and CD40, all of which are efficient antigen-processing
and presentation machinery [15, 16]. Ex vivo generated
DCs can be fused with whole tumor cells and reinfused
to the patients [17], or they can be used for ex vivo
induction and expansion of cytotoxic T lymphocytes (CTLs)
[18, 19]. Indeed, DCs/tumor fusion cell vaccines have been
shown to possess the elements essential for processing and
presenting tumor antigens to host immune cells for inducing
effective antitumor immune response and for breaking T-
cell tolerance to tumor-associated antigens in animal models
[12, 20]. Many animal studies have demonstrated that the
DCs/tumor fusion vaccine not only provided protection
against challenge with tumor cells, but also regressed estab-
lished tumors, including melanoma [21–27], colorectal [12–
14, 18, 28–35], breast [36–39], esophageal [40], pancreatic
[41], hepatocellular [42–46], lung [47, 48], laryngeal [49],
renal cell carcinoma [50], sarcoma [51–53], myeloma [54–
59], mastocytoma [60], and neuroblastoma [61].
In our initial study on DCs/tumor fusion cell vaccines,
murine MC38 adenocarcinoma cells stably transfected with
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human MUC1 (MC38/MUC1) were fused to synergistic
DCs derived from bone marrow in the presence of polyethy-
lene glycol (PEG). MUC1 that is a high-molecular-weight
glycoprotein that is overexpressed in breast, ovarian, and
pancreatic adenocarcinomas [62] represents a potential
target for active specific immunotherapy against certain
human tumors [5]. We have used MUC1-transgenic (MUC1.
Tg) mice that express MUC1 as a self-protein on normal
ductal epithelial cells. Because MUC1.Tg mice that express
MUC1 in a pattern and at a level similar to that found
in humans are unresponsive to MUC1 antigen, these mice
provide a potential model to assess the induction of anti-
MUC1 immune responses [63]. Vaccination of wild-type
mice with MUC1 RNA-transfected DCs (DCs/MUC1 RNA)
induced anti-MUC1 immune responses against MUC1-
positive MC38/MUC1, but not MUC1-negative tumor cells.
In contrast, there is little if any anti-MUC1 immunity
induced with the DCs/MUC1 RNA in MUC1.Tg mice
[5]. Interestingly, vaccination with fusions of DCs and
MC38/MUC1 tumor cells induced effective cellular and
humoral immunity against MUC1 antigen in MUC1.Tg
mice. The fusion vaccine provided protection against chal-
lenge with MUC1-positive tumor cells and mediated regres-
sion of established tumors in the mice. These findings
indicate that vaccination with the fusion cells can induce
CTLs against MUC1 and thereby reverse tolerance to
human MUC1 antigen [20]. Therefore, DCs/tumor fusion-
based vaccine may represent an effective strategy to induce
antitumor immunity, including MUC1-positive tumor cells.
Although the transplantable tumor models have been
contributed as the primary screening tools for cancer vaccine
development, they do not fit this criterion since the tumor
in these models grows very quickly, without the multiple
stages of cancer development found in human cancers. On
the other hand, genetically modified mice with spontaneous
development of carcinoma provide a powerful tool to
study the efficacy of tumor vaccines, since they mimic
cancer development in humans. We have used a double
transgenic mouse model expressing polyomavirus middle T
oncogene and human MUC1 as self-antigen to determine
the preventive effect of a DCs/tumor fusion cell vaccine.
Even in the genetically altered model of spontaneous breast
cancer, vaccination with DCs/tumor fusion cells conferred
sufficient antitumor immunity to block or delay mammary
tumor development [36, 37].
3. Antigen Presentation and Processing by
DCs/Tumor Fusions
Immature DCs display a characteristic phenotype with high
expression levels of MHC class I, class II, costimulatory
molecules (CD80 and CD86), low levels of the maturation
marker, CD83, but not TAAs. As compared with immature
DCs, mature DCs expressed much higher levels of HLA-DR,
CD80, CD86, and CD83. By contrast, almost all of tumors
expressed an abundance of TAAs, MHC class I, but not
MHC class II and costimulatory molecules. Fusion of DCs
and tumor cells resulted in the formation of a heterokaryon
that combined DC-derived MHC class I, class II, and
costimulatory molecules, efficient antigen-processing and
presentation machinery, and an abundance of tumor-derived
MHC class I and antigens [12]. After fusion, the cytoplasm
of DCs and tumor cells was integrated into one entry,
whereas their nuclei remained separate entities [64]. Such
a structure may make it possible to maintain the function
of both original live cells (DCs and tumor cells), at least in
part, including synthesis of TAAs, MHC class I, class II, and
costimulatory molecules. Moreover, the DCs/tumor fusions
also delivered not only proteins but also mRNA encoding
the whole TAAs from tumor cells. The DCs/tumor fusions
approach facilitates the entry of TAAs that are synthesized de
novo in the fusions into the endogenous antigen-processing
pathway of the DCs. Thus, the TAAs can be processed and
presented through both MHC class I and class II pathways on
the DCs in the context of costimulatory molecules [12]. The
advantage of DCs/tumor fusion vaccine over pulsing DCs
with tumor lysates is that endogenously synthesized antigens
have better access to MHC class I pathway [65]. In animal
studies, fusion vaccine was superior to DCs loaded with
antigenic protein or peptide, tumor cell lysates, or irradiated
tumor cells [25]. In human DCs/tumor fusions, it has been
also demonstrated that the tumor antigens were processed
through the endogenous pathway of DCs after fusion and T
cells primed by the fusions were high quality antigen-specific
cells, capable of mediating lysis of tumor targets [66]. In our
reports, we have created hybrid cells by fusing autologous
DCs and allogeneic tumor cell lines that did not express same
MHC class I molecules as autologous DCs [67, 68]. These
fusions expressed both MHC class I- and class II-restricted
tumor-associated epitopes through the cross-priming.
4. Activation of Antigen-Specific CD4+ and
CD8+ T Cells by DCs/Tumor Fusions
DCs reside at the port of entry, take up exogenous antigens,
and migrate to draining lymph nodes, where the antigens are
presented to CD4+ T cells through MHC class II pathways. In
addition, DCs are capable of initiating CD8+ T cell response
through a cross-presentation pathway [69, 70]. For cancer
vaccination, the goal is to generate antigen-loaded DCs
that efficiently stimulate robust and long-lasting CD4+ and
CD8+ T cell responses in the patient with cancer, with the
emphasis on “long-lasting” [71]. Importantly, vaccination
with the fusion cells is associated with activation of antigen-
specific CD4+ and CD8+ T cells [14, 19, 64]. To dissect the
role of MHC class I- or class II-restricted antigen-specific
T cell activation by the fusions, we have created various
types of DCs/tumor fusion cells by alternating fusion cell
partners using three kinds of knockout mice and wild type
mice: (1) wild type fusions (WT-FCs), (2) MHC class I
knockout fusions (IKO-FCs), (3) MHC class II knockout
fusions (IIKO-FCs), and (4) MHC class I and class II
double-knockout fusions (I/IIKO-FCs) [72]. In this study,
immunization of MUC1.Tg mice with WT-FCs, IKO-FCs,
IIKO-FCs, or I/IIKO-FCs provided 100%, 76.6%, 61.5%,
and 15.4% protection, respectively, against tumor challenge
with MC38/MUC1 tumor cells. This study has demonstrated
that MHC class II antigen presentation targeting activation
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of CD4+ T cells was indispensable in antitumor immunity.
The lower antitumor immunity by IIKO-FCs may be due
to lack of help from MHC class II-restricted CD4+ T cells
in the priming phase, whereas the induction of antitumor
immunity by IKO-FCs is through cross-priming by the host
DCs. The results suggest a novel mechanism of antitumor
immunity mediated by CD4+ T cells [72]. Previously, much
research has been devoted to the significance of CD8+ T
cells, given the fact that most tumors express only MHC
class I molecules and predominant effector cells are CD8+
CTLs. There is increasing evidence, however, that CD4+ T
cells play a more direct role, beyond delivery of assistance in
the generation of antitumor immunity [73]. In the priming
phase, CD4+ T cells activate APCs through the interaction
between CD40L and CD40, respectively, so that the educated
APCs acquire the capacity to stimulate CD8+ T cells [74].
CD4+ T cells also function to maintain the numbers
and cytotoxic capacity of CD8+ T cells and promote the
infiltration of CD8+ T cells into tumors [75]. Through cross-
priming, the fusion cells can activate antigen-specific CD4+
T cells that become multifunctional effectors producing IL-
2, IFN-γ, IL-4, and IL-10 [14, 19, 64]. Moreover, the fusion
cells also can function like APCs with the ability to migrate
to draining lymph nodes, where they reside in the T cell area,
interact with CD4+ and CD8+ T cells, and induce potent
antitumor immunity [14, 27]. Both direct stimulation and
cross-priming by host APCs participate in CD4+ and CD8+
T-cell activation by the fusion cells [14].
5. Antigen-Specific Polyclonal CTL Responses
Induced by DCs/Tumor Fusions
The priming and expansion of polyclonal CTLs by vaccines
has potential in vaccine applications for cancer. The goal of
the vaccines is to prime the patient’s own immune system to
recognize and destroy the tumor without harming normal
cells. Cancer vaccines that rely on induction of antitumor
immunity against a single antigen are potentially subject
to tumor-cell resistance mediated by downregulation of the
single antigen. Therefore, antigen-specific polyclonal CTL
responses have the potential to maximize the protection
against various subsets of tumor cells with down regulation
of certain tumor antigens, which may appear during the
course of tumor progression. DCs/tumor fusions are potent
inducers of antigen-specific polyclonal CD4+ T cells, which
are essential for the induction of augmented polyclonal
CTL responses against autologous tumor cells. Preclinical
human studies have demonstrated that the fusions could
induce antigens (CEA, MUC1, and WT1) specific CTLs
simultaneously in HLA-A2- and/or -A24-restrictive elements
in vitro [10, 19, 67, 76, 77]. Moreover, administration of
the polyclonal CTLs could regress tumors in SCID mice and
render mice free of disease up to the end of experiment [68].
In addition, DC/tumor fusion cells could be efficiently frozen
without loss of either antigen presentation potency or T
cell stimulatory capacity inducing polyclonal CTL responses
[76]. The cryopreserved DC/tumor fusion cells have poten-
tial applicability in the field of antitumor immunotherapy
and provide a platform for adoptive immunotherapy in the
clinical setting.
6. Generation of Regulatory T Cells (Treg) by
DCs/Tumor Fusions
Prevailing paradigms stipulate linear differentiation pro-
grams driving T cell lineage commitment, beginning with
naive T cells that become Th1, Th2, Tregs, or Th17 depend-
ing on the cytokine milieu, where the T cells encounter
at the time of antigenic stimulation. The presence of IL-
12 causes naive T cells to differentiate into Th1 cells; IL-
4 drives naive T cells to become Th2 cells; TGF-β drives
them to become Tregs, and TGF-β, together with IL-6
and IL-21, promotes Th17 cell development [78, 79]. The
cytokine milieu is associated with activated DCs, tumors,
cancer-associated fibroblasts (CAF), or tumor associated
macrophages (TAM). The control of immune-balance is
essential for the cancer therapy. There is increasing evidence
that DCs in situ induce antigen-specific unresponsiveness or
tolerance in central lymphoid organs and in the periphery.
The presentation of antigens to CD4+ or CD8+ T cells by
immature or partially mature DCs results in tolerance [80]
or induction of regulatory CD4+ and CD8+ T cells [81].
Tumors express or induce immunosuppressive cytokines
such as TGF-β and IL-10. As a result, tumor-antigen cross-
presentation by DCs induces T cell anergy or deletion and
Treg instead of antitumor immunity [82]. Indeed, it has
been reported that tumor progression correlated with an
accumulation of immature DCs that induced the expansion
of Tregs in lymphoid organs of tumor-bearing hosts [83].
Recently it has become possible to define Tregs on the
basis of their expression of the transcription factor forkhead
box protein 3 (Foxp3) [84]. Tregs have been shown to
exert their effects through the activities of TGF-β [85],
IL-10 [86], CTLA-4 [87], or through accumulation of
IL-2 via expression of CD25 [88]. Tumor-derived TGF-β
reduced the efficacy of DCs/tumor fusion vaccine via an
in vivo mechanism [28]. The blockade of tumor-derived
TGF-β reduced Tregs induction by the DCs/tumor fusions
vaccine and enhanced antitumor immunity [38]. We have
reported that the supernatant from human hepatocellular
carcinoma (HCC) cells induced functional impairment of
DCs as demonstrated by the downregulation of MHC
class I and class II, CD80, CD86, and CD83 molecules
[10]. Moreover, DCs exposed to the culture supernatants
from HCC cells secreting TGF-β failed to undergo full
maturation upon stimulation of TLR 4 agonist. Importantly,
fusions of DCs and HCC cells generated in the presence
of the culture supernatants from HCC cells promoted the
generation of CD4+ CD25high Foxp3+ Treg and inhibited
CTL induction. It has been demonstrated that CAF and
TAM synthesized proteins, such as VEGF, TGF-β, and IL-
10, all of which contributed to the local immunosuppressive
environment [89, 90]. A major obstacle to the development
of any active immunotherapeutic approach to cancer is the
immunosuppressive environment by the growing tumor.
Therefore, a combination of control of Treg and concomitant
induction of efficient polyclonal CTLs may be a more
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Figure 2: Fusions of autologous DCs and allogeneic tumor cells (DCs/allo-tumor). The DCs/allo-tumor can stimulate both CD4+ and CD8+
T cells as same as fusions of autologous DCs and autologous DCs (DCs/auto-tumor). Moreover, the DCs/allo-tumor can also stimulate
alloreactive T cells due to the presence of allogeneic HLA class I molecules from allogeneic tumor cells. Autologous MHC molecules present
foreign peptide derived from allogeneic tumor cells to T cell selected to recognize self MHC-foreign peptide complexes. In addition, T cell
also can recognize an allogeneic MHC molecule whose structure resembles the self MHC-foreign peptide complexes and structure formed
by both the allogeneic MHC molecules and the bound peptide.
effective immunotherapy to reduce recurrence and prolong
survival.
7. Modified Fusions of DCs and Tumor Cells
While DCs/tumor fusions approach has been developed in
animal studies, many adjuvants, including IL-2, IL-12, IL-
18, and synthetic oligodeoxynucleotides (ODNs) containing
specific bacterial unmethylated CpG motifs (CpG ODNs),
have been used to enhance the ability of DC/tumor fusion
vaccines to evoke antitumor immune responses [26, 29,
31, 54, 61]. These results suggest that the fusion vaccine
needs to be modified to enhance antitumor immunity.
The biggest advantage in DCs/tumor fusion strategy is that
modifications of DCs as well as tumor cells are independently
possible while their characters persist after the fusion.
This is an important difference between the DCs/tumor
fusion strategy and whole tumor lysates loading strategy.
Therefore, the therapeutic efficacy of a vaccine requires the
improved immunogenicity of both DCs and tumor cells. In
the absence of proper costimulation, antigen presentation
by DCs induces tolerance [1]. In particular, recent studies
suggest that Toll-like receptor- (TLR-) agonist CpG ODNs
or conserved pathogen-associated molecular patterns, such
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as penicillin-killed Streptococcus pyogenes (OK-432), start
the DC maturation process, which is a critical event in
the induction of full effector function in T cells. The
DCs stimulated with the TLR agonist, OK-432 (OK-DCs),
show higher expression levels of MHC class I and class
II, CD80, CD86, CD83, IL-12, and heat shock proteins
(HSPs) than do immature DCs [76]. On the other hand,
the immunogenicity of tumor cells can be improved by
heat-treatment [91]. Heat-treated autologous tumor cells
display a characteristic phenotype with increased expression
of HSPs, carcinoembryonic antigen (CEA), MUC1, and
MHC class I [77]. Intracellular HSPs play an important role
as molecular chaperones in cellular protein-folding pathways
[92]. Moreover, cross-priming is based on the transfer of
proteasome substrates that are transcriptionally upregulated
by heat treatment in human tumor cells [91, 93]. In contrast,
extracellular HSPs act as chaperon peptides and interact with
DCs in a receptor-mediated manner, leading to maturation
as well as proinflammatory responses [91, 94], all of which
are likely to be key danger signals to the antitumor immune
system. Therefore, we have created fusions of OK-DCs and
heat-treated tumor cells to elicit potent antitumor responses.
The modified fusions show to be active as demonstrated by
(1) up-regulation of multiple HSPs, MHC class I and class
II, CEA, CD80, CD86, CD83, and IL-12; (2) activation of
CD4+ and CD8+ T cells able to produce IFN-γ at higher
levels; (3) efficient induction of antigen-specific polyclonal
CTL activity against tumor targets; and (4) superior abilities
to induce CD107+ IFN-γ + CD8+ T cells and CD154+ IFN-
γ + CD4+ T cells. These fusions may provide a promising
means of inducing therapeutic antitumor immunity.
8. From Autologous to Allogeneic Tumor Cells
for DCs/Tumor Fusions
As a fusion partner, the advantage of using autologous tumor
cells is their possession of all the relevant TAAs required
for mounting effective antitumor immunity. However, in the
clinical setting of the patients with cancer, a major difficulty
for the DCs/tumor fusion vaccine is the preparation of
sufficient amounts of autologous tumor cells because of both
the availability of limited tumor samples and the difficulty in
culturing tumor cells. It has been reported that hybrid cells
generated by fusing DC from healthy donor with allogeneic
tumor cell line have induced CTL responses against the
allogeneic tumor cells used for fusion [95, 96]. The basis for
using allogeneic tumor cell lines instead of autologous tumor
cells is that some antigens are shared by most of tumors.
We have reported that fusions generated by autologous
DCs and allogeneic tumor cell lines can induce antigen-
specific polyclonal CTLs with cytotoxic activity against
autologous tumor cells (Figure 2) [67, 68]. This strategy has
numerous advantages. (a) Allogeneic tumor cell lines are well
characterized as TAA source. (b) Allogeneic tumor cell lines,
which shared with TAAs, can grow well in vitro; thus, there is
no limiting factor for preparation of tumor cells. (c) It is not
necessary to determine HLA typing of patients and allogeneic
tumor cells as a partner of fusion cells, because autologous
dendritic cells can process and present multiple TAAs from
allogeneic tumor cells in the context of MHC class I and class
II. Indeed, allogeneic tumor cells (melanoma and prostate
cancer), transduced with granulocyte-macrophage colony-
stimulating factor (GM-CSF), have been applied clinically
and shown to induce antitumor immunity [97, 98]. In this
trial, whole allogeneic tumor cells were genetically modified
to secrete the immune stimulatory cytokine, GM-CSF, and
then irradiated to prevent further cell division. After phase
III trials evaluating an allogeneic GVAX immunotherapy
in prostate cancer were finished, the trials have been
suspended. While currently explored allogeneic approaches
in whole tumor cell-based vaccination procedures represent
an improvement in terms of standardization over their
autologous counterparts, they nevertheless entail the culture
of large batches of cells under good manufacturing practice
(GMP) grade conditions [99]. Further optimization of these
in vitro culture methodologies is required. A major challenge
to develop an allogeneic tumor cell-based vaccine strategy is
to overcome the potential hazards of fetal calf serum (FCS)
that limit safety in clinical trials.
9. From Autologous to Allogeneic DCs
for DCs/Tumor Fusions
The rationale for using allogeneic DCs as a fusion partner
is based on the finding that a high frequency of unprimed
T cells from an individual react against the foreign MHC
antigens of another individual. Additional potential benefit
of using allogeneic DCs is that DCs from healthy donors
are readily available in unlimited amounts. DCs from cancer
patients may be defective in APC function, owing to cancer
treatment, such as chemotherapy and irradiation. It has
been demonstrated that fusions of both autologous and
allogeneic DCs are effective in inducing antitumor immunity
in human and animal models [100, 101]. The allogeneic
DCs/autologous tumor fusions express DCs-derived allo-
geneic HLA class II molecules and HLA class I molecules
derived from both DCs and tumor cells [102–104]. There
are mainly four cases using allogeneic DCs for fusions-
based vaccine. (a) Where there is no sharing of any MHC
molecules between allogeneic DCs and autologous tumor
cells, autologous MHC-class I restricted presentation of
tumor peptides by the DCs through cross-presentation is
not possible. (b) Where there is sharing of MHC class I
molecules, autologous MHC-class I restricted presentation
of tumor peptides by the DCs through cross-presentation is
possible. The direct CD4+ T cell response to the allogeneic
MHC class II antigens on allogeneic DCs will provide potent
T cell help for the generation of antigen-specific CD8+
CTL responses to autologous tumor peptides presented by
the shared MHC class I molecules. (c) Where there is
sharing of MHC class II molecules, autologous MHC-class
IL restricted presentation of tumor peptides by the DCs
through cross-presentation is possible. The direct CD4+ T
cell response to the semi-allogeneic MHC class II antigens
on semi-allogeneic DCs will provide potent T cell help for
the generation of antigen-specific CD4+ T cell response
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to autologous tumor peptides presented by the shared
MHC class II molecules. (d) Where there is some sharing
of both MHC class I and class II molecules, the fusions
express allogeneic MHC class I and class II molecules
derived from semi-allogeneic DCs for direct stimulation
of the patient’s CD4+ T cells as well as all the patient’s
HLA class I and class II molecules for autologous MHC-
restricted tumor peptide presentation. The alloreactive T
cell response by semiallogeneic fusions might help for the
initiation and expansion of antigen-specific responses to
autologous tumors by autologous MHC-restricted elements.
Therefore, where there is no sharing of MHC molecules
between allogeneic DCs and autologous tumor cells, efficient
antitumor immunity may not be induced in therapeutic
experiment [51]. Semiallogeneic fusions may be effective to
induce antigen-specific polyclonal CTL responses. Indeed,
semiallogeneic fusions elicited a significantly stronger anti-
tumor immunity than did by syngeneic fusions in animal
studies [31, 34]. However, it has also been reported that
expression of self MHC by semiallogeneic fusions could
induce antigen-specific immunity; however, concurrently
activated allogeneic bystander responses do not provide
helper or adjuvant effects [105]. In clinical trials, both
autologous and allogeneic DCs fused with autologous tumor
cells have been more effective as vaccines in the induction of
CTL responses and antitumor activities [106, 107].
10. HSP70-Peptide Complexes Derived
from DCs/Tumor Fusions
Heat shock proteins (HSPs) play a primary role as intra-
cellular molecular chaperones in the pathways of antigenic
protein folding within the cell [108]. The HSP/peptide
complexes can be taken by DCs through receptors and
presented in MHC class I and class II molecules on DCs
[109]. This phenomenon leads to activation of maturation
and representation of peptide antigen cargo of HSPs by DCs
and initiates antigen-specific polyclonal CTL responses [92].
In several clinical trials, autologous HSP/peptide complexes
have induced CTLs against autologous targets [110]. To
improve the potency of chaperone protein-based vaccine,
we have produced an improved HSP70-based vaccine with
the use of DCs/tumor fusions [111]. The HSP70/peptide
complexes (HSP70.PC) derived from DCs/tumor fusions
were especially different from those derived from tumor
cells in enhanced association with immunologic peptides
in animal models. The HSP70.PC derived from the fusions
have increased their immunogenicity and therefore may
constitute an improved formulation of chaperone protein-
based tumor vaccine. Recently, it has been also reported
that human DCs pulsed with HSP70.PC extracted from
DCs/tumor fusions enhanced CTL responses significantly
more than that obtained from DCs pulsed with HSP70.PC
from DCs pulsed with tumor cell lysates [112]. Therefore,
this is an alternative molecular chaperone-based cancer
vaccine using DCs/tumor fusions. Future studies should be
required to improve the field of the chaperone-based cancer
vaccine.
11. Clinical Trials
Based on the unique features of fusion cell based vaccines
and the observations of tumor eradication in animal studies,
initial Phase I/II clinical trials with fusion vaccines have been
conducted in a variety of tumors (Table 1). Fusions vacci-
nation was first reported in patients with melanoma [113,
114]. The fusions of allogeneic DCs and autologous tumor
were irradiated and injected subcutaneously as a vaccine.
Seven of the 16 patients responded to the vaccination, one
with complete response, one with partial response, and five
with stable disease following to previous rapid progression.
Similar results in patients with melanoma were reported
from another group [116, 117]. In our initial clinical trials
of fusions-based vaccination, eight patients with malignant
glioma were treated with fusions of autologous DCs and
autologous tumor cells. Vaccination with fusions resulted in
immunological responses and two patients showed partial
responses, indicating that limited success has occurred
in clinical trials. To enhance clinical responses, we had
conducted a Phase I/II clinical trials for the vaccination
with low dose of recombinant human (rh) IL-12 in patients
with malignant brain tumor, gastric, colorectal, ovarian
carcinoma, and melanoma [115, 118]. Eleven out of 15
patients with malignant glioma achieved a stable response
and 24 patients had a progressive disease after 8 weeks
of the initial treatment [115]. No serious adverse effects
were observed. In four patients, magnetic resonance imaging
showed a greater than 50% reduction in tumor size. One
patient had a mixed response. Therefore, administration of
fusions and rhIL-12 can induce more effective antitumor
effects than fusions alone in some patients with malignant
glioma. These data are compatible with the results from
mouse brain tumor model in which administration of
fusions and rIL-12 markedly prolonged the survival of mice
with brain tumors compared with fusions or rIL-12 alone
[119]. Moreover, vaccination of autologous fusions alone
in patients with breast, renal, colorectal, and gastric cancer
resulted in immunological responses. Interestingly, two out
of 10 patients with metastatic breast cancer exhibited disease
regression, including a near complete response of a large
chest wall mass [17]. Five out of 13 patients with renal
carcinoma and one out of 10 patient with breast cancer
had disease stabilization [17]. This group has also evaluated
the effect of vaccination with fusions of allogeneic DCs and
autologous tumor cells in patients with renal cell carcinoma
[106]. Vaccination of patients with stage IV renal cell
carcinoma with allogeneic DCs/autologous tumor fusions
resulted in immunologic and clinical responses in a subset
of patients. Two out of 21 patients demonstrated a partial
clinical response and 8 patients with had stabilization of
their disease. In clinical trials, only limited therapeutic results
are obtained. One of the reasons is that all patients were
in advanced stage and extremely small amounts of fusions
are used. Fusions-based vaccine may work more effectively
in patients in the early stage of the disease with low tumor
burden. Moreover, patients with a still uncompromised
immune system are expected to respond best to the vaccine.
Fusions-based vaccine may be used in combination with
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Table 1: Asessment of the fusions vaccine.
Fusions
Tumor Dendritic cell Tumor Adjuvant Patients (n) Clinical response Ref.
Melanoma Allogeneic Autologous 16 1 (CR) [113, 114]
1 (PR)
5 (SD)
9 (PD)
Glioma Autologous Autologous 8 2 (PR) [115]
1 (SD)
5 (PD)
Melanoma Autologous Autologous 17 1 (PR) [116]
1 (SD)
15 (PD)
Melanoma Allogeneic Autologous rh IL-2 11 1 (SD) [117]
10 (PD)
Glioma Autologous Autologous rh IL-12 12 3 (PR) [115, 118]
2 (MR)
4 (SD)
3 (PD)
Breast cancer Autologous Autologous rh IL-12 2 1 (SD) [115, 118]
1 (PD)
Gastric/Colorectal
carcinoma
Autologous Autologous rh IL-12 3 1 (SD) [115, 118]
2 (PD)
Ovarian carcinoma Autologous Autologous rh IL-12 3 2 (SD) [115, 118]
1 (PD)
Melanoma Autologous Autologous rh IL-12 4 4 (PD) [115, 118]
Breast cancer Autologous Autologous 10 2 (PR) [17]
1 (SD)
7 (PD)
Renal cell carcinoma Autologous Autologous 13 5 (SD) [17]
8 (PD)
Renal cell carcinoma Allogeneic Autologous 20 2 (PR) [106]
8 (SD)
10 (PD)
Hepatocellular
carcinoma
Autologous Autologous 1 1 (PD) [10]
Renal cell carcinoma Allogeneic Autologous 10 1 (PR) [107]
6 (SD)
3 (PD)
CR: complete response; PR: partial response; MR: mixed response; SD: stable disease; PD: progressive disease.
conventional therapies, including surgery, chemotherapy, or
irradiation.
12. Future View
The DCs/tumor fusions vaccine has been successfully used
in mice models. Moreover, human DCs/tumor fusions have
enormous potential activities to induce polyclonal CTL
responses against autologous targets in vitro. However, the
overall rate of clinical responses remains to be low. Fusions
vaccine alone may be insufficient to have a significant contri-
bution to treat advanced cancer patients. There are increasing
evidences that tumor-derived soluble factors promote the
induction of tolerance through the generation of CD4+
CD25highFoxp3+ Treg subset, which is linked to compro-
mised immune responses in patients with advanced cancer
[120]. Moreover, it has recently been reported that DCs are
capable of inducing conversion of naive CD4+ T cells to
adaptive CD4+ CD25+ Foxp3+ Treg in the presence of TGF-
β or IL-10 derived from tumor cells [121]. We have also
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reported that soluble factors derived from tumor cells pro-
moted the generation of CD4+ CD25high Foxp3+ Treg and
inhibited CTL induction by fusions [10]. The elimination of
immunosuppressive immune cells, including Tregs, myeloid
derived suppressor cells (MDSCs), or tumor-associated
macrophages (TAMs), may improve clinical responses. In
animal study, enhancement of antitumor immunity can be
induced with a combination of fusions and regulatory T
cell depletion in pancreatic cancer bearing mice [41]. More
importantly, in a Phase I/II clinical trial, partial removal
of Tregs can further enhance DC vaccine-induced immune
responses in cancer patients [122]. The combination of direct
enhancement of CTL function and concomitant inhibition of
Treg function through blockade of cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) on both cell types is essential
for mediating the full therapeutic effects of anti-CTLA-
4 antibodies in cancer immunotherapy. Another approach
would be to enhance T cell costimulation by administering
agonistic antibodies specific for 4-1BB [123], OX40 [124],
cytotoxic T lymphocyte-associated antigen 4 (CTLA4) [125],
or programmed death 1 (PD-1) [126]. It has been reported
that a common pathway of endogenous OX40 interaction
is critical for the development of a therapeutic immune
response by fusions vaccination [127]. The pathological
interactions between cancer cells and host immune cells in
the tumor microenvironment create an immunosuppressive
network that promotes tumor growth, protects the tumor
from immune attack, and attenuates immunotherapeutic
efficacy. Therefore, it is also essential to develop interventions
that counter the propensity of tumors to evade immune
elimination, such as immunization against the tumor stroma
cells [128].
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